{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-007533","form_type":"8-K","ticker":"CNSP","cik":"0001729427","company_name":"CNS Pharmaceuticals, Inc.","filed_at":"2024-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.386631+00:00","generated_at":"2026-05-30T06:59:36.750828+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nasdaq panel grants CNS Pharmaceuticals temporary exception until March 11, 2025 to meet bid price rule","bullets":["Company received Nasdaq deficiency notice on Sept 12, 2024 for bid price below $1.00 for 30 consecutive days.","Not eligible for standard 180-day compliance period due to cumulative reverse stock splits of 250:1 or more in prior two years.","After hearing, Nasdaq panel granted exception until March 11, 2025 to regain compliance.","Panel reserves right to reconsider; Listing Council may review within 45 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-007533","json":"https://secwatch.observer/filing/0001683168-24-007533.json","markdown":"https://secwatch.observer/filing/0001683168-24-007533.md","text":"https://secwatch.observer/filing/0001683168-24-007533.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824007533/0001683168-24-007533-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824007533/cns_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:59:36.750828+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001193125-26-251517","ticker":"LESL","company_name":"Leslie's, Inc.","filed_at":"2026-06-01T20:28:42+00:00","headline":"Leslie's regains Nasdaq compliance for minimum market value of publicly held shares","event_type":"regulatory","sec_items":["8.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251517","json":"https://secwatch.observer/filing/0001193125-26-251517.json","markdown":"https://secwatch.observer/filing/0001193125-26-251517.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821806/000119312526251517/0001193125-26-251517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821806/000119312526251517/lesl-20260529.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-068659","ticker":"OTLK","company_name":"Outlook Therapeutics, Inc.","filed_at":"2026-06-01T13:15:32+00:00","headline":"Outlook Therapeutics resubmits BLA for ONS-5010 to FDA; Class 1 review, PDUFA in 60 days","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068659","json":"https://secwatch.observer/filing/0001104659-26-068659.json","markdown":"https://secwatch.observer/filing/0001104659-26-068659.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926068659/0001104659-26-068659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926068659/tm2616461d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-068591","ticker":"VYGR","company_name":"Voyager Therapeutics, Inc.","filed_at":"2026-06-01T12:00:26+00:00","headline":"FDA clears IND for VY1706, Voyager's tau-silencing gene therapy for Alzheimer's","event_type":"regulatory","sec_items":["8.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068591","json":"https://secwatch.observer/filing/0001104659-26-068591.json","markdown":"https://secwatch.observer/filing/0001104659-26-068591.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926068591/0001104659-26-068591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926068591/tm2616041d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001476840-26-000050","ticker":"EXFY","company_name":"Expensify, Inc.","filed_at":"2026-05-29T21:15:09+00:00","headline":"Expensify regains Nasdaq minimum bid price compliance","event_type":"regulatory","sec_items":["8.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001476840-26-000050","json":"https://secwatch.observer/filing/0001476840-26-000050.json","markdown":"https://secwatch.observer/filing/0001476840-26-000050.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1476840/000147684026000050/0001476840-26-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1476840/000147684026000050/exfy-20260528.htm"},"side_by_side_evidence":null},{"accession":"0001178913-26-002988","ticker":"SLXN","company_name":"Silexion Therapeutics Corp","filed_at":"2026-05-29T11:00:25+00:00","headline":"Silexion Therapeutics completes 1-for-10 reverse share split; warrants adjusted","event_type":"regulatory","sec_items":["3.03","5.03","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-002988","json":"https://secwatch.observer/filing/0001178913-26-002988.json","markdown":"https://secwatch.observer/filing/0001178913-26-002988.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002988/0001178913-26-002988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002988/zk2635442.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-062172","ticker":"RR","company_name":"RICHTECH ROBOTICS INC.","filed_at":"2026-05-28T20:49:32+00:00","headline":"Richtech Robotics receives Nasdaq delisting notice for late Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062172","json":"https://secwatch.observer/filing/0001213900-26-062172.json","markdown":"https://secwatch.observer/filing/0001213900-26-062172.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1963685/000121390026062172/0001213900-26-062172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1963685/000121390026062172/ea0292546-8k_richtech.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-243074","ticker":"MNKD","company_name":"MANNKIND CORP","filed_at":"2026-05-28T12:37:11+00:00","headline":"FDA releases MannKind from Afrezza malignancy study; sBLA for children PDUFA May 29","event_type":"regulatory","sec_items":["8.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-243074","json":"https://secwatch.observer/filing/0001193125-26-243074.json","markdown":"https://secwatch.observer/filing/0001193125-26-243074.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000119312526243074/0001193125-26-243074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000119312526243074/mnkd-20260527.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-025419","ticker":"SNAL","company_name":"Snail, Inc.","filed_at":"2026-05-27T20:25:45+00:00","headline":"Snail receives Nasdaq extension to Sept 22, 2026 to regain listing compliance","event_type":"regulatory","sec_items":["8.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025419","json":"https://secwatch.observer/filing/0001493152-26-025419.json","markdown":"https://secwatch.observer/filing/0001493152-26-025419.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1886894/000149315226025419/0001493152-26-025419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1886894/000149315226025419/form8-k.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}